Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1 by Xu, Fengfeng L et al.
RESEARCH ARTICLE Open Access
Mitotic slippage in non-cancer cells induced by a
microtubule disruptor, disorazole C1
Fengfeng L Xu
1, Youssef Rbaibi
1, Kirill Kiselyov
1, John S Lazo
2, Peter Wipf
3, William S Saunders
1*
Abstract
Background: Disorazoles are polyene macrodiolides isolated from a myxobacterium fermentation broth. Disorazole
C1 was newly synthesized and found to depolymerize microtubules and cause mitotic arrest. Here we examined
the cellular responses to disorazole C1 in both non-cancer and cancer cells and compared our results to vinblastine
and taxol.
Results: In non-cancer cells, disorazole C1 induced a prolonged mitotic arrest, followed by mitotic slippage, as
confirmed by live cell imaging and cell cycle analysis. This mitotic slippage was associated with cyclin B
degradation, but did not require p53. Four assays for apoptosis, including western blotting for poly(ADP-ribose)
polymerase cleavage, microscopic analyses for cytochrome C release and annexin V staining, and gel
electrophoresis examination for DNA laddering, were conducted and demonstrated little induction of apoptosis in
non-cancer cells treated with disorazole C1. On the contrary, we observed an activated apoptotic pathway in
cancer cells, suggesting that normal and malignant cells respond differently to disorazole C1.
Conclusion: Our studies demonstrate that non-cancer cells undergo mitotic slippage in a cyclin B-dependent and
p53-independent manner after prolonged mitotic arrest caused by disorazole C1. In contrast, cancer cells induce
the apoptotic pathway after disorazole C1 treatment, indicating a possibly significant therapeutic window for this
compound.
Background
Microtubules are dynamic polymers that facilitate trans-
port and movement within the cell [1]. Microtubule
dynamics are a critical aspect of mitosis, ensuring accu-
rate chromosome capture and segregation [1,2]. Factors
that interfere with microtubule attachment keep the
mitotic spindle checkpoint unsatisfied, thus causing
mitotic arrest and inhibition of cell proliferation [3].
Microtubule dynamics can be modified by two groups
of chemical inhibitors. The first group, represented by
taxanes, stabilizes microtubules and is clinically used to
treat breast, lung, bladder and head and neck cancers
[4]. The second group of modifiers include vinblastine,
vincristine, and vinorelbine, disrupt microtubules and
are used in the treatment of leukemia, lymphoma, small
cell lung and breast cancer, and other malignancies [5].
Although these chemotherapeutic drugs are efficacious,
new drug development is still needed due to intrinsic
and acquired drug resistance and untoward actions of
existing therapeutics.
Intensive research has focused on the responses of
cancer cells to microtubule inhibitors, and it is known
that apoptosis is a common outcome triggered by either
p53-dependent or p53-independent pathways [[6,7] and
references within]. However, the response of non-trans-
formed cells to microtubule inhibitors is less well under-
stood. Contrasting the response of non-cancer cells and
tumor cells should enhance our understanding of the
effects of microtubule inhibitors on cancer patients.
The disorazoles are a family of natural compounds
isolated from the fermentation broth of the myxobac-
teria Sorangium cellulosum [8]. Disorazole A1,o n eo f
the major components, was demonstrated to disrupt
microtubules, leading to mitotic arrest and eventually
apoptosis [9]. Disorazole C1 (DZ), a relatively minor
constituent of the fermentation mixture, was obtained
synthetically since it was considered to have greater
therapeutic potential due to the absence of the chemi-
cally reactive divinyl oxirane and (E, Z)-dienyl oxazole
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cause microtubule depolymerization and mitotic arrest
during a small molecule screen [11]. In this paper, we
further examined the cellular responses to DZ and com-
pared our results to two known microtubule inhibitors,
vinblastine (VBL) and taxol (TXL).
Results
1. DZ has the classical properties of microtubule
inhibitors, including mitotic arrest and inhibition of cell
proliferation
To analyze the effect of DZ on microtubules, we pre-
formed indirect immunofluorescence on immortalized
retinal pigmented epithelial cells (RPE-hTERT) treated
with 10 nM of DZ, a concentration similar to DZ’sI C 50
concentrations in several tested cell lines [12]. One hour
after DZ was added, microtubules were observed to
have retracted from the cell periphery, confirming that
DZ depolymerized microtubules and showing that the
overall disruption was more severe at the distal plus
ends (Figure 1a). Similar results were observed in cancer
cells treated with DZ (data not shown).
One property that microtubule inhibitors share is that
they cause mitotic arrest by activating or preventing the
satisfaction of the spindle assembly checkpoint [3].
DAPI-staining of chromosomes was used to demon-
strate an increase in the mitotic index in both non-can-
cer and cancer cells 16 hours after DZ treatment (Figure
1b). Similar results were observed using phosphorylated
histone H3 staining (data not shown).
Finally, cell proliferation is typically blocked by micro-
tubule disruption. After treatment with 10 nM of DZ,
the proliferation of immortalized human foreskin fibro-
blast cells (HFF-hTERT) was inhibited, as determined by
the MTS assay (Figure 1c). Similar results were also
obtained in RPE-hTERT cells (Additional file 2). In
summary, DZ disrupts microtubules, arrests cells in
mitosis and inhibits cell proliferation, similar to classical
tubulin inhibitors.
2. After a prolonged mitotic arrest, cells treated with DZ
underwent mitotic slippage
After 38-hour treatment with 10 nM of DZ, many RPE-
hTERT cells showed fragmented nuclei (Figure 2a),
which were also observed in VBL or TXL treated cells
(data not shown). This nuclear fragmentation was not
due to apoptosis in these cells as demonstrated by low
annexin-V staining (Figure 2b); rather, it was similar to
the phenotype observed in cells abnormally exiting from
a prolonged mitotic arrest, referred to as mitotic slippage
[13]. To test directly whether mitotic slippage was occur-
ring in response to DZ treatment, we exploited live cell
imaging. Due to the low transfection efficiency of RPE-
hTERT cells, we examined UPCI:SCC40 cells (an oral
squamous cell carcinoma cell line, a gift of Dr. Susanne
Gollin, University of Pittsburgh) stably-transfected with
GFP-tagged histone H2B. After treatment with 10 nM of
DZ for 16 hrs, most of the observed mitotic cells exited
mitosis to form fragmented nuclei with decondensed
chromosomes (Figure 2c, also see the movie in Addi-
tional file 3) within the 9.5 hour recording window (note
that the arrow in Figure 2c points to the same cell at dif-
ferent time points). Of 23 cells arrested in mitosis, we
found that 70% of them (16/23) underwent mitotic slip-
page, forming fragmented and decondensed micronuclei
similar to the example shown in Figure 2c. An additional
13% of cells underwent mitotic slippage and then cell
death, which was characterized by chromosome decon-
densation shortly followed by recondensation and frag-
mentation of the chromatin into many small pieces.
Another 13% of cells underwent a mitotic catastrophe,
characterized by many small and highly condensed chro-
matin fragments formed directly from mitotic arrested
cells. Finally, additional cells (~4%) maintained the mito-
tic arrest; these cells may be entering cellular senescence,
seen previously with DZ treatment [12].
To confirm that mitotic slippage was the source of the
fragmented nuclei in the majority of the population,
serum starvation was used to arrest cells in G1. After a
38-hour treatment with 10 nM of DZ, less than 5% of the
serum-starved RPE-hTERT cells showed fragmented
nuclei, indicating that the observed nuclear fragmenta-
tion required progression through the cell cycle (Figure
2d). Similar results were obtained in hydroxyurea-treated
cells, which were arrested in S phase, confirming that the
nuclear fragmentation required transit through mitosis
(Figure 2d). Although the cycling cells were able to
escape the DZ-induced arrest, they did not resume a nor-
mal cell cycle but arrested again in G1, as indicated by
FACS analysis at 38 hours of DZ exposure (Figure 2e).
Interestingly, upon examination of those fragmented
micronuclei, filaments were found to accumulate around
them forming a thick bundle, as shown by electron
microscopy (Figure 3a). These filaments stain positive
with anti-tubulin antibodies by immunofluorescence
(Figure 3b) and we believe they are variants of the
microtubule structures seen in untreated cells. Similar
perinuclear accumulation of microtubule-like structures
was seen previously with a vinca alkaloid microtubule
inhibitor [14]. The microtubules appear to be forming
an abnormal array around the micronuclei, which might
contribute to the fragmentation observed after DZ treat-
ment, but this will require further analysis.
3. Mitotic slippage in non-cancer cells induced by DZ is
correlated with cyclin B degradation
Previous studies indicate that mitotic slippage occurs via
slow cyclin B degradation and abrogation of the mitotic
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tein level of cyclin B accumulated up to 36 hours in
RPE-hTERT cells upon DZ treatment and then sharply
decreased (Figure 4a). Similarly, the percentage of cells
undergoing mitotic slippage began to peak at 36 hours
(Figure 4b), suggesting that cyclin B degradation was
also associated with mitotic slippage after DZ treatment.
To study whether protein degradation was required
for the observed mitotic slippage, we used the protease
inhibitor MG132 to block cyclin B degradation. In
MG132-treated cells, the percentage of cells undergoing
mitotic slippage was dramatically reduced while the
mitotic index remained high, indicating that cells
blocked for proteasomal protein degradation were less
likely to undergo mitotic slippage from DZ (Figure 4c).
Our data support the conclusion that cyclin B degrada-
tion was correlated with mitotic slippage in non-cancer
cells after DZ treatment.
4. p53 is stabilized after DZ treatment, but p53 is not
required for mitotic slippage
Elevated levels of p53 have been observed previously in
cells treated with microtubule inhibitors [17], and there-
fore their role in mitotic slippage was examined here.
As demonstrated in Figure 5a, p53 accumulated in RPE-
hTERT cells after DZ treatment, comparable to that
seen with VBL or TXL treatment. However, the activa-
tion of p53 was not essential for mitotic slippage, as
siRNA knockdown of p53 in RPE-hTERT cells did not
diminish the frequency of fragmented nuclei (Figure 5b).
To further confirm this, we used human foreskin fibro-
blasts transformed with a plasmid expressing human tel-
omerase with wild-type p53 (HFF-hTERT vector only)
or a stable-knockdown of p53 (HFF-hTERT shp53; a
gift from Dr. Edward Prochownik, University of Pitts-
burgh). No reduction of mitotic slippage was observed
in cells unable to express p53, thus confirming that p53
was not required (Figure 5c).
5. Non-cancer cells undergo mitotic slippage after DZ
treatment without activating apoptotic pathways, while
cancer cells execute apoptosis
Although mitotic slippage was previously considered a
survival pathway to protect cells from apoptosis [18],
emerging studies have shown that mitotic slippage can
also be coupled to apoptosis [19-21]. To study whether
apoptosis was responsible for the mitotic slippage from
DZ exposure, we preformed four tests. Only 15% of the
RPE-hTERT cells were annexin-V positive, suggesting
far fewer cells underwent apoptosis than nuclear
Figure 1 DZ depolymerizes microtubules from the plus-ends, arrests cells in mitosis and inhibits cell proliferation. a) Depolymerization
of microtubules. RPE-hTERT cells were treated with 10 nM of DZ for 1 hour, fixed and stained with antibody against a-tubulin. Arrows indicate
the retracted microtubules. b) Mitotic arrest. UPCI:SCC103 and RPE-hTERT cells were treated with 50 nM of DZ for 16 hours and visualized by
DAPI staining. c) Inhibition of cell proliferation as determined by the MTS assay (Promega). HFF-hTERT cells were treated with 10 nM of DZ, 100
nM of VBL or 1 μM of TXL for the indicated times. Results are averages of two experiments.
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tages of nuclear fragmentation did not decrease when
caspase inhibitors were used (Figure 6a), indicating that
mitotic slippage was independent of apoptosis. Addition-
ally, other apoptotic markers were also analyzed. These
markers include: 1) cytochrome C staining, demonstrat-
ing little release of cytochrome C after DZ treatment
compared to the H2O2 control (Figure 6b, Additional
file 4); 2) mitochondrial membrane potential indicator
MitoTracker, revealing little loss of mitochondrial mem-
brane potential upon DZ treatment compared to the
H2O2 control (Figure 6b); and 3) poly(ADP-ribose) poly-
merase (PARP) cleavage, also revealing little or no apop-
tosis (Figure 6c).
Even when cells were treated with DZ for 68 or 72
hours, very little apoptosis was observed (data not
shown). Furthermore, other non-cancer cell lines, such
as HFF-hTERT (immortalized human foreskin fibro-
blasts) and UP3 cells (primary human oral cells grown
in culture), also showed very little or no PARP cleavage
after 38 hours of 10 nM DZ treatment (Additional file
5). Additionally, DNA ladder formation was not
observed in RPE-hTERT cells exposed to DZ (Addi-
tional file 6). Taken together, our results indicate that
the apoptotic pathway was not activated in the RPE-
hTERT cells exposed to DZ. However, PARP cleavage
was strongly observed in all the tested cancer cell lines
(Figure 6d), suggesting apoptosis pathway was activated
in malignant cells by DZ.
Discussion
DZ is a naturally existing compound that has been
recently synthesized to evaluate its potential as a cancer
therapeutic. In our study, DZ treatment demonstrated a
disruption of microtubules from the plus end, consistent
with its proven ability to bind tubulin [12], indicating
that the mechanism of action of DZ is similar to that of
other classical microtubule d i s r u p t o r s .H o w e v e r ,D Z
treatment seemed to show stronger mitotic slippage
than VBL in RPE-hTERT cells (Figure 2d), suggesting
Figure 2 Mitotic slippage after DZ treatment. a) Fragmented nuclei (arrows) in RPE-hTERT cells treated with either DMSO as a control or 10
nM of DZ for 38 hours and visualized by DAPI staining. b) Percentage of annexin-V positive cells (apoptotic cells) in untreated RPE-hTERT cells
and RPE-hTERT cells treated with 10 nM of DZ, 100 nM of VBL, 1 uM of TXL for 38 hours. c) Live cell imaging of mitotic slippage. UPCI:SCC40
cells stably-transfected with GFP-H2B were pre-treated with 10 nM of DZ for 16 hours before analysis (also see the movie in Additional file 3).
Arrow points to a cell that is first in mitosis and then undergoing mitotic slippage resulting in abnormally shaped nuclei. Timestamps: hours:
minutes. d) Percentages of the fragmented nuclei (mitotic slippage) in cycling RPE-hTERT cells and RPE-hTERT cells arrested in the different
phases of cell cycle. Serum-starvation or 4 mM hydroxyurea (HU) were used to stop cell cycling prior to the treatment with 10 nM of DZ, 100
nM of VBL, 1 μM of TXL for 38 hours. Results were averages of three independent experiments. e) Flow cytometry analysis of DNA content. RPE-
hTERT cells were treated with 10 nM of DZ for 38 hours. Data are representative for three independent experiments.
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Page 4 of 10Figure 3 Microtubule filaments form around nuclei after DZ treatment. a) Electron microscopy analysis of the nuclei in untreated RPE-
hTERT cells and RPE-hTERT cells treated with 10 nM of DZ for 38 hours. A white arrow indicates the microtubule-like structures around the
fragmented nucleus in the blowout image. b) Immunofluorescence microscopy analysis of tubulin structures in untreated RPE-hTERT cells and
RPE-hTERT cells treated with 10 nM of DZ, 100 nM of VBL, 1 μM of TXL for 38 hours. Arrows indicate the microtubule-like structures around the
fragmented nucleus labeled by anti-tubulin antibodies. un: untreated.
Figure 4 Cyclin B degradation is correlated with mitotic slippage.R P E - h T E R Tc e l l sw e r et r e a t e dw i t h1 0n Mo fD Zi nt h ef o l l o w i n g
experiments. a) Immunoblot analysis of cyclin B during a time course from 4 to 48 hours. Actin was a loading control. b) Percentages of
fragmented nuclei analyzed at the same time points as in a. c) Upper panel: a schematic experimental design. Cells were treated with DZ for 47
hours. 5 μM MG132 was added 23 hours after DZ was added to avoid a lethal toxicity effect on the cells. Lower panels: cyclin B protein levels
and percentages of fragmented nuclei analyzed as in above experiments. Data are representative for three independent experiments.
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destabilizers.
Previous studies of microtubule inhibitors’ effects on
non-transformed cells have been limited to a DNA con-
tent-based analysis of cell cycle distribution. Researchers
have observed an accumulation of cells with a 4N DNA
content in the second cell cycle following mitosis,
referred to as mitotic slippage [22]. However, the cause
of this phenotype is not fully understood. Recently,
Brito and Rieder showed that mitotic slippage after
nocodazole treatment occurs when the spindle-assembly
checkpoint (SAC) fails to prevent a slow but continuous
proteolysis of cyclin B [16]. In the current study, we
observed that mitotic slippage after DZ treatment was
also correlated with cyclin B degradation.
p53 has been demonstrated to play a major role in cell
cycle control [23]; thus it may also be involved in mito-
tic slippage. In the p53-knockdown RPE-hTERT cells
there was no loss of fragmentation; indicating that p53
was not required for mitotic slippage in the presence of
this microtubule inhibitor. In fact, there was a consistent
increase in mitotic slippage in the transient p53 knock-
down cells. This could be due to p53 down-regulation
of cdc20 [24], which is demonstrated to be required for
the proteolysis of cyclin B by activating anaphase-pro-
moting complex, a mitotic ubiquitin ligase [25]. By
knocking down p53, cdc20 levels may increase, thus
activating more ubiquitin ligase complexes and promot-
ing cyclin B degradation. Alternatively, the observed
increase in the percentage of cells undergoing mitotic
Figure 5 p53 is stabilized after DZ treatment, but is not required for mitotic slippage. IR: ionizing radiation, commonly used for inducing
p53 in p53 knockdown cells to detect the efficiency of the siRNA knockdown. a) Immunoblot analyses of p53 in RPE-hTERT cells after indicated
treatment. Upper panel: cells were treated with 10 nM of DZ for indicated time. Lower panel: cells were treated with 10 nM of DZ, 100 nM of
VBL or 1 μM of TXL for 38 hours. b) Left panel: immunoblot analysis of p53 in RPE-hTERT p53-wild type and p53-knockdown cells. Right panel:
percentages of fragmented nuclei in RPE-hTERT p53-wild type and p53-knockdown cells treated with 10 nM of DZ for 38 hours. Graph shows
the average of three independent experiments. c) Upper panel: immunoblot analysis of p53 in HFF-hTERT vector only and HFF-hTERT shp53
(stable-knockdown) cells. Lower panel: percentages of fragmented nuclei in HFF-hTERT vector only and HFF-hTERT shp53 cells treated with 10
nM of DZ, 100 nM of VBL or 1 μM of TXL for 38 hours. Results in graph are averages of three independent experiments.
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p53 knockdown, which can increase the frequency of
cells passing through mitosis. However, we did not see
an increase in mitotic slippage with the stable p53
knockdown and this relationship will thus require
further study.
It has been demonstrated that after mitotic slippage,
non-cancer cells can be arrested in the next G1 stage in
a p53-dependent manner [15,22]. Similarly, after DZ
treatment, we also observed an accumulation of cells
with a 4N DNA content (Figure 2e), as well as an induc-
tion of p53 (Figure 5a), which is similar to the postmito-
tic G1 arrest of TXL-treated non-cancer cells [15].
Hence, we suggest that when non-cancer cells are trea-
ted with microtubule inhibitors, for example DZ, they
m a yh a v et w o“checkpoints” sequentially to ensure the
fidelity of cell division. The first one is SAC, which can
cause mitotic arrest if microtubules are disrupted [25].
If SAC is not effective enough, cells may slip out from
mitotic arrest and become arrested in the next G1 stage
[15,16,22]. Based on our data and previous studies, it is
plausible that p53 facilitates both of these “checkpoints”
after microtubule disruption as described in the model
(Figure 7).
p53 has often been found compromised in human
cancer tissues [26]. In our study, p53 is either truncated
(UPCI:SCC103) or undetectable (HeLa) in cancer cell
lines (data not shown). This indicates that the apoptosis
triggered by DZ in cancer cells may be p53-independent.
Finally, our data suggest that after exposure to a cer-
tain concentration of DZ (10 nM in this study), cancer
cells tend to execute apoptosis while non-cancer cells
undergo mitotic slippage without activating the apopto-
tic pathways, indicating that non-cancer and cancer cells
respond differently after DZ treatment. Those cells that
do not die from apoptosis may become senescent, a
phenotype discussed previously [[12] and references
within].
Conclusions
In this study, we analyzed the cellular response to a
synthesized natural product, DZ. Although mitotic arrest
induced by DZ was observed in both non-cancer and
cancer cells, these cells had different fates. Non-cancer
cells escaped from mitotic arrest (mitotic slippage) in a
cyclin B-dependent and p53-independent manner with-
out apoptosis. In contrast, cancer cells activated the
apoptosis pathway. These differential responses observed
after DZ treatment were similar to the effects of vinblas-
tine or taxol, suggesting a promising therapeutic poten-
tial of DZ.
Methods
Cell cultures and treatments
HFF-hTERT vector only (human foreskin fibroblast
immortalized with human telomerase reverse transcrip-
tase) and HFF-hTERT shp53 (stable-knockdown of p53)
cells (gifts from Dr. Edward Prochownik, University of
Pittsburgh) were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS) and 1% L-glutamine.
RPE-HTERT cells (retinal pigmented epithelial cell line
stably transfected with human telomerase reverse
Figure 6 Non-cancer cells undergo mitotic slippage without activating apoptotic pathways while cancer cells execute apoptosis after
DZ treatment. Cells were treated with 10 nM of DZ for 38 hours in the following experiments unless where indicated. 100 nM of VBL and 1
μM of TXL were used as controls. RPE-hTERT cells were used in (a-c). a) cas-inh: Caspase inhibitors (caspase-3/7, -8, and -9 inhibitors). Results are
averages of three independent experiments. b) Upper panel: cytochrome C staining. Lower panel: MitoTracker staining. c) Immunoblot analysis of
PARP. Upper band: full-length PARP. Lower band: cleaved product of PARP. d) Immunoblot analysis of PARP cleavage in cancer cells after DZ
treatment. un: untreated.
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mented with 10% FBS. All UPCI:SCC cells (oral squa-
mous carcinomas cells, gifts from Dr. Susanne Gollin,
University of Pittsburgh) were maintained in MEM sup-
plemented with 10% FBS and 1% non-essential amino
acid. UP3 (uvulopalatopharyngoplasty) cells (gift from
Dr. Susanne Gollin) were maintained in KGM2 medium.
U2OS cells (ATCC) were maintained in McCoy’s5 A
supplemented with 10% FBS. Generally, cells were trea-
t e dw i t h1 0n MD Zo r1 0 0n Mv i n b l a s t i n eo r1μM
taxol for 38 hours at 37°C before analysis, unless where
indicated. Vinblastine concentration was chosen to
demonstrate a similar level of microtubule disruption
compared with 10 nM of DZ. Cell permeable caspase
inhibitors (caspase-3/7, -8, -9 inhibitors) (Calbiochem)
were used as in reference Jennings JJ et al., 2006 [27].
Immunofluorescence
Cells were fixed in 3.7% paraformaldehyde at room tem-
perature for 15 minutes followed by 7 minute-incuba-
tion of 0.1% triton X-100 at 4°C. Primary a-tubulin
antibodies (Abcam, Cambridge, MA) or cytochrome C
antibodies (Santa Cruz) were detected with the applica-
tion of Alexa Fluor488 or 568 (Molecular Probes, Invi-
trogen) as the secondary antibodies. All antibodies were
diluted in 1% bovine serum albumin (BSA)/PBS. DNA-
specific fluorescent dye 4,6-diamidino-2-phenylindole
(DAPI; Sigma, St. Louis) was used to visualize DNA.
The samples were examined using a 40× or 100× oil
immersion objective (UPlanApo) at an Olympus BX60
epifluorescence microscope. Images were taken using a
Hamamatsu Argus-20 CCD camera (Hamamatsu Co.,
Bridgewater, NJ)
Live cell imaging
Cells were seeded on 35-mm glass-bottom culture dish
(MatTek Corporation, Ashland, MA) and treated with
DZ at a final concentration of 10 nM for 16 hours
before analysis. Epifluorescence microscopy was per-
formed on a Nikon TE2000-U inverted microscope with
a CoolSNAP HQ digital camera (Roper Scientific Photo-
metrics) while cells were maintained at 37°C in a
Figure 7 Model: response of non-cancer cells to microtubule inhibitors. Disorazole is proposed to activate two sequential cell cycle
checkpoints. The first is the APC-dependent arrest at mitosis; when that fails, a second arrest at G1 is observed. p53 stabilization may mediate
both events but is not required for the mitotic slippage that acts independent of the traditional p53-dependent apoptosis pathways. APC/C:
anaphase-promoting complex/cyclosome.
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Imaging Services, Reinach, Switzerland). Images were
taken and analyzed using MetaMorph software (Molecu-
lar Devices).
Western Blotting
Antibodies against cyclin B (BD, San Jose, CA), actin
(Cytoskeleton, Denver, CO), p53 (Santa Cruz Biotech-
nology, Santa Cruz, CA), PARP (Cell Signaling Technol-
ogy, Danvers, MA) were used as primary antibodies and
all diluted in 5% milk/Tris-buffered Saline with 0.5%
Tween-20 (TBST). Anti-mouse or anti-rabbit IgG-HRP-
linked secondary antibodies (Amersham, GE Healthcare,
UK) were also diluted in 5% milk/TBST. Results were
visualized using enhanced chemiluminescent kit (Pierce).
Cell proliferation and apoptosis assays
Cell proliferation was measured using the MTS assay kit
(Promega; tetrazolium compound [3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt; MTS]) following the manu-
facture’s instruction. In annexin-V assays, Tetramethyl
Rhodamine Methyl Ester (TMRM) diluted in regular
buffer was used to stain mitochondria at 37°C for 10
minutes before the addition of annexin-V (Molecular
Probes, Invitrogen, CA) following the manufacture’s
instruction. MitoTracker (Invitrogen, CA) staining was
performed following the manufacture’s protocol.
Flow cytometry
Cells were fixed with cold 70% EtOH and stained with
propidium iodide (Fluka: BioChemika, Switzerland) at a
final concentration of 50 μg/ml. Analysis of flow cyto-
metry was performed in Flow Cytometry Facility in Uni-
versity of Pittsburgh Cancer Institute (UPCI).
p53 knockdown
Cells were seeded onto 60-mm culture dishes five hour
before siRNA transfection. sip53 (Qiagen) was trans-
fected into cells using HiPerFect Transfection Reagent
(Qiagen) following the manufacture’s instruction.
Electron microscopy
Cells grown on plastic dishes were fixed in 2.5% glutar-
aldehyde or paraformaldehyde in 0.1 M Na-cacodylate
(30 min), washed with 0.1 M Na-cacodylate, post-fixed
with 1% OsO4, washed with PBS and stained for 30 min
with 2% uranyl acetate. Following dehydration in 30% to
100% ethanol, the samples were embedded in resin by
immersion in 30% to 100% resin:propylene oxide mix-
tures. Fixed samples were mounted on grids and ana-
lyzed with a JEOL 100CX transmission electron
microscope.
Additional file 1: Figure S1. Structures of disorazole A1 and DZ.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S1.PNG]
Additional file 2: Figure S2. Proliferation assay of RPE-hTERT cells
treated with DZ and VBL, indicating that DZ inhibited growth of RPE-
hTERT cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S2.PNG]
Additional file 3: Supplemental Movie. Cells were treated with 10 nM
of DZ for 16 hours before imaging. Cells escaped from mitotic arrest and
formed abnormally shaped nuclei, indicating mitotic slippage had
occurred.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S3.WMV]
Additional file 4: Figure S3.H 2O2-treated cells demonstrating
cytochrome C release retained normal microtubule structures. Left panel:
a-tubulin staining. Right panel: cytochrome C staining.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S4.PNG]
Additional file 5: Figure S4. Only little or no PARP cleavage was
observed in UP3 (primary cells) and HFF-hTERT (non-cancer cells) after
DZ treatment. un: untreated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S5.PNG]
Additional file 6: Figure S5. DNA fragmentation assay using untreated
REP-hTERT cells and RPE-hTERT cells treated with DZ revealed little DNA
laddering upon DZ treatment (left panel) while H2O2-treated RPE-hTERT
cells demonstrated DNA laddering (right panel). An arrow indicates DNA
ladder, a marker of apoptosis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6769-10-1-
S6.PNG]
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